Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network
Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 1815-1825
DOI: 10.1111/dom.16175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.01.2025. Verfasst von Sophie Lamothe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseas…. Hauptthemen laut MEDLINE: Lipodystrophy, Familial Partial, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French Ministry of Solidarity and Health, Assistance Publique-Hôpitaux de Paris, Sorbonne University, France.
Abstract (Originalsprache)
Aim
To describe the effects of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) in patients with familial partial lipodystrophy (FPLD) assessed in a real‐life setting in a national reference network. Patients and Methods We retrospectively collected clinical and metabolic parameters in patients with FPLD in the French lipodystrophy reference network, who initiated GLP‐1RA. Data were recorded before, at one‐year (12 ± 6 months) and at the latest follow‐up on GLP‐1RA therapy (≥18 months).
Results
Seventy‐six patients (89.4% of women), diagnosed with LMNA ‐related FPLD2 ( n = 57), PPARG ‐related FPLD3 ( n = 4), PLIN1 ‐related FPLD4 ( n = 5) or FPLD1 ( n = 10) initiated GLP‐1RA therapy between 2008 and 2024. Patients were aged a median (IQR) 48 years (34.5–57), body mass index (BMI) was 26.0 kg/m 2 (23.9–29.5), HbA1c 8.3% (7.5–9.3), triglycerides 2.31 mmol/L (1.62–3.88). GLP‐1RA were used in addition to previously used antidiabetics, 50% of patients being insulin‐treated. After one year with GLP‐1RA therapy, BMI, HbA1c and triglycerides significantly decreased to 25.6 kg/m 2 (22.7–29.1), 7.3% (6.6–8.3) and 1.97 mmol/L (1.5–3.2) respectively ( p < 0.001, p < 0.001 and p < 0.01, respectively), without significant changes in other antidiabetic and lipid‐lowering drugs. Gamma‐glutamyl‐transferase and alanine‐aminotransferase levels also significantly decreased. Effects on HbA1c, BMI and triglycerides persisted in the long term. One case of acute pancreatitis occurred during follow‐up, associated with severe hypertriglyceridemia in a non‐observant patient. Gastrointestinal symptoms affected 34% of patients, leading to GLP‐1RA withdrawal in six patients.
Conclusion
GLP‐1RA significantly improved BMI, HbA1c and triglycerides in a large majority of patients with FPLD. Larger and prospective controlled studies are warranted for identification of predictive factors and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, Franc…
- Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.
- Department of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.
- Department of Endocrinology, Diabetology and Nutrition CHU La Milétrie, Poitiers, France.
- Department of Nutrition, Metabolic Diseases, Endocrinology, Aix Marseille University, Inserm, INRA, C2VN, La Conception Hospital, Marseille, France.
- Department of Endocrinology, Diabetes and Nutrition, Reims University Hospital, Hospital Robert-Debré, Reims, France.
ORCID-Profile: Sophie Lamothe, Corinne Vigouroux
Förderung
- French Ministry of Solidarity and Health
- Assistance Publique-Hôpitaux de Paris
- Sorbonne University, France
- Corinne Vigouroux represents PRISIS in the European Reference Network on Rare Endocrine Conditions - Project ID No 739527
- Assistance Publique - Hôpitaux de Paris
- Sorbonne Université
Zitieren
APA
Lamothe, S., Belalem, I., Vantyghem, M. C., Nobecourt, E., Mosbah, H., Béliard, S., Delemer, B., Dupuis, H., Vandenbroere, P., Scheyer, N., Amouyal, C., Hadjadj, S., Janmaat, S., Vigouroux, C., & Vatier, C. (2025). Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network. Diabetes, Obesity and Metabolism, 27(4), 1815-1825. https://doi.org/10.1111/dom.16175
Vancouver
Lamothe S, Belalem I, Vantyghem MC, Nobecourt E, Mosbah H, Béliard S, et al. Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network. Diabetes, Obesity and Metabolism. 2025;27(4):1815-1825. doi:10.1111/dom.16175
BibTeX
@article{Lamothe2025,
author = {Lamothe, Sophie and Belalem, Ines and Vantyghem, Marie-Christine and Nobecourt, Estelle and Mosbah, Héléna and Béliard, Sophie and Delemer, Brigitte and Dupuis, Hippolyte and Vandenbroere, Paul and Scheyer, Nicolas and Amouyal, Chloé and Hadjadj, Samy and Janmaat, Sonja and Vigouroux, Corinne and Vatier, Camille},
title = {Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {4},
pages = {1815--1825},
doi = {10.1111/dom.16175}
}
EUVIMED